GleamWall
中文EN

PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Laboratory Analytical Instruments · Nasdaq · SEC CIK 1299130 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY2.0%
TTM net income YoY75.0%
TTM EPS YoY81.2%
Revenue 3-yr CAGR2.9%
Net income 3-yr CAGR—

Margins

Gross margin36.4%
Operating margin-83.5%
Net margin-82.5%
FCF margin-77.5%
EBITDA margin-77.4%

Returns

ROE-929.3%
ROA-16.7%
ROIC (approx.)—
Asset turnover0.20x

Leverage & solvency

Liabilities / assets104.4%
Debt / equity—
Current ratio4.92x
Interest coverage-18.15x

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue3.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$40.56M$39.01M$37.18M$44.65M$38.44M$39.77M$37.15M$39.22M
Cost of revenue$27.09M$26.37M$24.34M$28.08M$22.54M$25.08M$38.52M$29.17M
Gross profit$13.47M$12.64M$12.84M$16.57M$15.90M$14.68M-$1.37M$10.06M
R&D expense$20.22M$23.02M$19.61M$22.88M$22.85M$22.53M$29.05M$27.47M
SG&A expense$29.42M$33.39M$31.15M$34.05M$31.10M$36.17M$40.17M$41.64M
Operating income-$37.00M-$44.61M-$8.36M-$41.20M-$38.88M-$44.85M-$428.93M-$153.03M
Interest expense$2.06M$2.11M$1.74M$1.74M$1.74M$1.74M$1.74M$2.76M
Pretax income-$37.58M-$44.68M-$8.09M-$40.17M-$37.62M-$41.90M-$426.38M$2.69M
Income tax$269,000$58,000$184,000$202,000$383,000$35,000-$302,000$316,000
Net income-$37.85M-$44.74M-$8.28M-$40.37M-$38.00M-$41.93M-$426.07M$2.37M
EBITDA-$34.54M-$42.29M-$6.16M-$38.46M-$36.42M-$42.19M-$423.80M-$150.19M
EPS (basic)-0.12-0.14-0.03—-0.13-0.14-1.44—
EPS (diluted)-0.12-0.14-0.03—-0.13-0.14-1.44—
Weighted avg. shares (diluted)311.25M310.65M305.82M—300.84M300.16M296.86M—
Balance sheet
Cash & equivalents$55.91M$61.00M$56.27M$63.71M$56.47M$54.80M$58.51M$57.59M
Short-term investments$143.51M$175.87M$219.69M$215.80M$242.19M$259.93M$284.60M$334.56M
Receivables$38.32M$31.10M$29.35M$35.45M$30.62M$32.26M$31.64M$27.52M
Inventory$60.28M$61.08M$51.02M$49.28M$53.15M$53.84M$54.01M$58.76M
Current assets$307.85M$338.64M$369.52M$375.05M$394.24M$413.40M$444.92M$495.68M
PP&E, net$29.28M$26.97M$24.38M$24.15M$22.13M$23.10M$24.79M$30.50M
Goodwill$317.76M$317.76M$317.76M$317.76M$317.76M$317.76M$317.76M$317.76M
Intangibles$12.16M$13.08M$14.10M$15.12M$16.14M$17.16M$18.18M$389.57M
Total assets$721.10M$751.85M$782.37M$784.08M$803.16M$825.47M$860.79M$1.26B
Current liabilities$66.59M$68.81M$65.36M$72.83M$63.21M$59.75M$66.60M$66.30M
Short-term debt———————$0
Total liabilities$782.48M$785.06M$780.00M$778.73M$767.07M$763.98M$769.15M$753.85M
Shareholders' equity-$61.38M-$33.21M$2.37M$5.35M$36.09M$61.49M$91.64M$506.59M
Shares outstanding312.24M310.81M310.49M301.96M301.85M300.35M300.04M294.42M
Cash flow statement
Operating cash flow-$37.60M-$35.58M-$44.69M-$19.07M-$18.71M-$29.38M-$44.06M-$30.65M
Capital expenditure$988,000$1.55M$3.04M$861,000-$86,000$550,000$1.39M$1.62M
Free cash flow-$38.59M-$37.14M-$47.73M-$19.93M-$18.62M-$29.93M-$45.45M-$32.27M
Investing cash flow$31.11M$40.07M$35.86M$26.03M$18.90M$25.28M$45.23M$58.24M
Financing cash flow$1.46M$255,000$1.44M$0$1.47M$0$1.96M-$50.20M
Depreciation & amortization$2.46M$2.32M$2.20M$2.74M$2.46M$2.66M$5.13M$2.84M
Stock-based compensation$8.54M$9.26M$4.46M$9.59M$10.98M$11.89M$9.20M$16.03M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.